860636P
Avanti
Glucosyl(β) Sphingosine-d5
Avanti Research™ - A Croda Brand
Synonym(s):
D-glucosyl-β-1,1′-D-erythro-sphingosine-d5
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C24H42D5NO7
CAS Number:
Molecular Weight:
466.66
UNSPSC Code:
12352211
NACRES:
NA.25
Recommended Products
form
powder
packaging
pkg of 1 × 1 mg (860636P-1mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
shipped in
dry ice
storage temp.
−20°C
SMILES string
[H][C@](/C=C/CCCCCCCCCCCC([2H])(C([2H])([2H])[2H])[2H])(O)[C@](N)([H])CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O
Application
Glucosyl(β) Sphingosine-d5 has been used as an internal standard for the quantification of lysohexosylceramide in various samples by liquid chromatography-tandem mass spectrometry.
Biochem/physiol Actions
Glucosyl sphingosine has an ability to regulate Ca2+ release in the brain microsomes. It acts as a potential biomarker for Gaucher disease (GD).
Packaging
5 mL Amber Glass Screw Cap Vial (860636P-1mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
also commonly purchased with this product
Product No.
Description
Pricing
Storage Class Code
11 - Combustible Solids
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
LC-MS/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: a novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease
Pettazzoni M, et al.
PLoS ONE, 12(7) (2017)
LC-MS/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: a novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease
Pettazzoni M, et al.
Testing, 12(7) (2017)
Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients
Rolfs A, et al.
PLoS ONE, 8(11) (2013)
Mercedes Roca-Espiau et al.
Journal of orthopaedic surgery and research, 14(1), 383-383 (2019-11-23)
Chronic fatigue (CFg) is a prevalent symptom in Gaucher disease (GD) at diagnosis (79%) and remains in a quarter of patients after years of therapy. Bone abnormalities are present in over 70% and peripheral neuropathy in about 11% of the
Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease
Schiffer V, et al.
PLoS ONE, 15(1), e0227077-e0227077 (2020)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service